The mammalian SWI/SNF chromatin remodeling complex is composed of more than 10 protein subunits, and plays important roles in epigenetic regulation. Each complex includes a single BRG1 or Brm molecule as the catalytic subunit. We previously reported that loss of Brm, but not BRG1, causes transcriptional gene silencing of murine leukemia virus-based retrovirus vectors. To understand the biological function and biogenesis of Brm protein, we examined seven cell lines derived from various human tumors that do not produce Brm protein. We show here that these Brm-deficient cell lines transcribe the Brm genes efficiently as detected by nuclear run-on transcription assay, whereas Brm mRNA and Brm hnRNA were undetectable by reverse transcription-polymerase chain reaction analysis. These results indicate that expression of Brm is strongly and promptly suppressed at the posttranscriptional level, through processing and transport of the primary transcript or through stability of mature Brm mRNA. This suppression was attenuated by transient treatment of these cell lines with HDAC inhibitors probably through indirect mechanism. Importantly, all of the treated cells showed prolonged induction of Brm expression after the removal of HDAC inhibitors, and acquired the ability to maintain retroviral gene expression. These results indicate that these Brm-deficient human tumor cell lines carry a functional Brm gene. Treatment with HDAC inhibitors or introduction of exogenous Brm into Brm-deficient cell lines significantly reduced the oncogenic potential as assessed by colonyforming activity in soft agar or invasion into collagen gel, indicating that, like BRG1, Brm is involved in tumor suppression.
Introduction
The SWI/SNF complex contributes to the regulation of gene expression by altering the chromatin structure, and plays many important roles in epigenetic regulation in many organisms (Narlikar et al., 2002) . In mammals, this complex is composed of more than 10 subunits, and each of the complex contains a single molecule of either Brm or BRG1, but not both (Wang et al., 1996) . These two proteins are the catalytic subunits and have DNA-dependent ATPase activity that drives remodeling of nucleosomes (Laurent et al., 1993) . We previously reported that Brm and BRG1 have clear differences in their biological activities; Brm is essential for maintenance of murine leukemia virus (MuLV)-based retroviral gene expression, whereas BRG1 is not (Mizutani et al., 2002) . Therefore, cell lines that do not express detectable levels of Brm protein (designated hereafter as Brm-deficient cell lines) undergo very rapid retroviral gene silencing that occurs stochastically and discontinuously.
The SWI/SNF complex interacts with various proteins through many specific interfaces of its different subunits. These interacting proteins include products of proto-oncogenes such as c-fos, c-jun (Ito et al., 2001) , and c-myc (Cheng et al., 1999) , and tumor suppressor proteins such as Rb (Dunaief et al., 1994; Trouche et al., 1997; Strobeck et al., 2000) , p53 , and b-catenin (Barker et al., 2001) . We previously reported that the heterodimer of c-Fos and c-Jun requires functional SWI/SNF complex for transactivation through AP-1 DNA binding sites (Ito et al., 2001) . Therefore, this complex would be involved in multiple processes associated with formation or suppression of tumors.
Genetic and molecular evidence indicate that some subunits of the SWI/SNF complex act as tumor suppressors in human and mice. The Ini1 subunit is deleted in malignant rhabdoid tumors, which occur commonly in pediatric brains and kidneys in the first 2 years of human life (Versteege et al., 1998; DeCristofaro et al., 1999) . In addition, loss of heterozygosity of Ini1 gene causes rhabdoid tumors in heterozygous ( þ /À) knockout mice (Klochendler-Yeivin et al., 2000; Roberts et al., 2000; Guidi et al., 2001) . Therefore, Ini1 gene is now categorized as a typical tumor suppressor gene. The expression of BRG1 subunit is sometimes deleted in non-small cell lung carcinomas (Reisman et al., 2003) and other cancers (Wong et al., 2000; DeCristofaro et al., 2001) . Besides, experiments on BRG1 knockout mice revealed that heterozygous ( þ /À) mice were prone to developing tumors (Bultman et al., 2000) , suggesting that BRG1 is a tumor suppressor gene.
Brm, which has very similar structure to BRG1, has been also reported to be deficient in several human cell lines derived from various human tumors (Dunaief et al., 1994; Mizutani et al., 2002; Iba et al., 2003; Reisman et al., 2003) . However, Brm was previously shown to be dispensable in mice, and Brm homozygotes were not prone to developing tumors (Reyes et al., 1998) . Therefore, biological meanings of frequent loss of Brm expression accompanied with tumor formation were not clear at present. Interestingly, expression of Brm has not been detected in several human tumor cell lines , and some cell lines such as SW13 were reported not to produce BRG1 protein either (Dunaief et al., 1994) . In our previous report, we showed that this cell line comprises two subtypes: SW13(vimÀ), which expresses neither Brm nor BRG1, and SW13(vim þ ), which produces both proteins (Yamamichi-Nishina et al., 2003) . We also found that in both SW13(vim-) and SW13(vim þ ) cells, the BRG1 and Brm genes were transcribed efficiently, but that in SW13(vim-) cells, mRNA expression and protein production of BRG1 and Brm were tightly suppressed, indicating that the regulation is at the post-transcriptional level.
In the present work, we selected several Brm-deficient cell lines derived from a wide variety of human tumors, and studied the molecular mechanisms underlying the loss of Brm protein production. Our results indicate that Brm deficiency is not caused by mutation or deletion in the Brm locus, but caused by post-transcriptional regulation of the Brm gene in all the Brm-deficient cell lines tested here, and that this unique regulation is independent of expression status of BRG1 protein or BRG1 mRNA. We also observed that HDAC inhibitors attenuate suppression of Brm expression in these cells, and induction of either endogenous or exogeneous Brm reduced the oncogenic potential of these Brm-deficient cell lines.
Results
The Brm gene is transcribed constitutively in human tumor cell lines deficient in Brm expression
We screened expression of Brm, BRG1 and Ini1 proteins and mRNAs in many cell lines derived from a wide variety of human tumors, and some of them are summarized in Table 1 . Including those previously reported, seven Brm-deficient cell lines (SW13(vim-), C33A, PA-1, NCC-IT, NCI-H522, A427, and G401), five BRG1-deficient cell lines (SW13(vim-), NCI-H522, A427, H1299, and A549), and two Ini1-deficient cell lines (G401 and A204) were identified by Western blotting analysis. As shown in Table 1 , some cell lines, such as G401 and A427, lacked expression of two proteins simultaneously among these three proteins. Brm mRNA was not detected in all the seven Brm-deficient cell lines, when reverse transcriptionpolymerase chain reaction (RT-PCR) was performed with two independent pairs of primers ( Figure 1a ). On Table 1 Expression of Brm, BRG1 and Ini1 in several human tumor cell lines
Cell line
Origin Brm BRG1 Ini1
Non-small-cell lung carcinoma
Non-small-cell lung carcinoma (Wong et al., 2000; Betz et al., 2002) . To examine whether the Brm gene is largely defected or arranged in the seven Brm-deficient cell lines, we isolated genomic DNA and performed the PCR analysis using two pairs of primers, which cover fourth exon and 34th exon. The expected PCR products were clearly detected in all the Brm-deficient cell lines as well as MDA-MB435 and HeLa-S3 cells, which were used for control cell lines competent for the SWI/SNF complex (data not shown). Next, to elucidate the suppressive regulation of the Brm gene, a series of nuclear run-on transcription assays was performed. At first, we performed a set of run-on transcription assays with nuclear extracts of three Brm-deficient cell lines, SW13(vim-), C33A and PA-1 (Figure 1b) . We used three independent DNA probes from the 5 0 -, central, and 3 0 -regions of the Brm cDNA, and found that these Brm-deficient cell lines transcribe the Brm gene as efficiently as MDA-MB435 cells. In addition, the relative levels of transcription of the 5 0 -, central, and 3 0 -regions of the Brm gene were similar in these cell lines, regardless of the status of mRNA and protein production (Figure 1a ). These results suggest that both initiation and elongation of the Brm transcription in the Brm-deficient cell lines proceed as efficiently as those in Brm-expressing cells. When CD44 and collagenase cDNA probes were used for the nuclear run-on assay, active transcription was detectable in nuclei isolated from MDA-MB435, whereas no signal was detected in those from SW13(vim-) (Figure 1b) . These results are consistent with the observation that SW13(vim-) cells never express both of two genes at the transcriptional level (Ito et al., 2001; YamamichiNishina et al., 2003) , confirming that the run-on transcription assay faithfully reflects transcriptional activity in these cells.
We performed an additional set of run-on transcription assays with nuclear extracts of three other Brmdeficient human cell lines, NCC-IT, NCI-H522, and A427 ( Figure 1c) ; and found that these three Brmdeficient cell lines also transcribe the Brm gene as efficiently as MDA-MB435 cells. We also checked the transcription of a mouse embryonic stem cell line EB5, which do not express Brm mRNA (data not shown), as has been reported for mouse embryonic cells in early development (LeGouy et al., 1998 , and PA-1). Brm(F), Brm(G), and Brm(H) were DNA probes originated from the 5 0 -, center, and 3 0 -regions of the Brm cDNA, respectively. Brm(F) and Brm(H), respectively, cover the 5-and 3 0 -region amplified by RT-PCR shown in (a). DNA probes for b-actin and empty vector plasmid (control) were used for positive and negative controls. To certify the accuracy of run-on analysis, probes for CD44 and collangease, which are under the control of transcription factor AP-1 that requires the SWI/SNF complex for its activity (Ito et al., 2001) , were added. (c) Run-on transcription assay with nuclear extracts of four Brm-deficient cells (NCC-IT, NCI-H522, A427, and EB5), and two Brm-expressing cells . DNA probes for BRG1 and Brm were derived from the corresponding full-length cDNA Biogenesis and antioncogenic potential of Brm N Yamamichi et al Brm hnRNA is undetectable in the Brm-deficient cell lines
To elucidate molecular mechanisms of post-transcriptional suppression of the Brm gene in Brm-deficient cell lines, we performed RT-PCR analysis to detect parts of Brm hnRNA using two primer pairs covering 5 0 -region (third intron and fourth exon) and 3 0 -region (32nd intron and 33rd exon) of the primary transcript. Both regions were clearly detectable in MDA-MB435 and HeLa-S3 cells (Figure 2 ). However, in most of the Brmdeficient cell lines neither regions were detected, and only in NCC-IT, the trace of RT-PCR product was detectable. These results indicate that there is only marginal amounts of Brm primary transcripts in Brmdeficient cell lines immediately after the transcription, suggesting that post-transcriptional suppression of the Brm gene starts at very early stages. The presence of a small amount of hnRNA in NCC-IT cells would be reflecting a rather high level of Brm transcription as judged by the nuclear run-on assay (Figure 1c) , and further suggests that post-transcriptional suppression of Brm may be operating also in later stages, such as nuclear export or mRNA instability.
Transient treatment with HDAC inhibitors induces prolonged expression of Brm protein in Brm-deficient cell lines
In all the Brm-deficient cell lines tested here, the Brm gene locus seemed to be at least not largely arranged, as the fourth and 34th exons of Brm gene were detectable by genomic PCR, and also because nuclear run-on transcription assays showed both initiation and elongation of the Brm transcript proceed efficiently (Figure 1b and c). Considering that the Brm gene expression is epigenetically regulated in these cell lines, several reagents were screened for their ability to induce Brm protein expression, and we found that HDAC inhibitor such as FK228 (Nakajima et al., 1998; Furumai et al., 2002) or CHAP31 (Komatsu et al., 2001) can efficiently induce Brm protein production in all seven Brmdeficient tumor cell lines (Figrue 3, Table 2 ). Both FK228 and CHAP31 target class I HDACs including HDAC1 and HDAC2. Induction of Brm protein production was always accompanied by increased expression of Brm mRNA, as monitored by RT-PCR ( Figure 3 ). In contrast, Brm protein levels in Brmexpressing cell lines were not affected significantly by the HDAC inhibitor treatment ( Figure 3 ). As the initiation and elongation of the Brm transcript proceeds efficiently in all the Brm-deficient cell lines, this induction cannot be explained by the direct effect on the transcription of the Brm gene. Therefore, these results suggest that HDAC inhibitors indirectly attenuate post-transcriptional suppression of Brm through induction of other genes.
When BRG1 and Ini1 were analyzed by Western blotting of the same cell lysates, production of BRG1 in BRG1-deficient cell lines was not induced after the treatment of HDAC inhibitors, and similar results were obtained with respect to Ini1 ( Figure 3 , Table 2 ). The only one exception was SW13(vim-) cells, in which production of BRG1 protein was induced by the HDAC inhibitors. Post-transcriptional suppression of BRG1 observed specifically in SW13(vim-) (Yamamichi-Nishina et al., 2003) is also shown to be released by this Table 2 for 3 days. Under these conditions, no growth inhibition or cytotoxic effects were observed. All the cultures were grown in the absence of the inhibitor for additional 24 h, and were disrupted for preparing total cell protein under denaturing conditions or total RNA. Brm, BRG1, and Ini1 protein expression was analysed by Western blotting (upper panel), and Brm mRNA was detected by semiquantitative RT-PCR using two independent pairs of primers (lower panel). Protein bands (arrows) of Brm (190 kDa), BRG1 (190 kDa), and Ini1 (47 kDa) were detected by immunostaining with the corresponding specific antisera reagent. These results suggest that deficiency in BRG1 expression can be caused by the several different mechanisms, in contrast to a rather common mechanism of post-transcriptional suppression observed in Brmdeficient cell lines. Therefore, it is difficult at present to propose a simple model, which explain why there are so frequent cases of concomitant loss of Brm and BRG1 protein in human tumor cell lines and original tumors (Table 1; Wong et al., 2000; DeCristofaro et al., 2001; Reisman et al., 2002) . Next, to examine how HDAC inhibitors influence expression of Brm, we monitored the kinetics of Brm protein expression in SW13(vim-) and A427 cells after HDAC inhibitor treatment (Figure 4 ). In both cell types, Brm levels were unchanged for 1-3 days after removal of the inhibitor, and significant expression was detected until day 7, whereas Brm levels decreased considerably on day 10, and became marginal on day 14. RT-PCR analysis of SW13(vim-) cells revealed that kinetics of Brm mRNA was similar to that of Brm protein level: Brm mRNA was strongly induced by the HDAC inhibitor treatment (Figure 4 ). Since production of primary Brm transcript in untreated SW13(vim-) was efficient (Figure 1b) , it is indicated that transient treatment with HDAC inhibitors would repair attenuated processing of the Brm primary transcript into mRNA.
The major targets of HDACs are acetylated histones in the chromatin. Therefore, addition of HDAC inhibitors should rapidly increase acetylation of histones, and removal of HDAC inhibitors would be expected to reduce amounts of acetylated histones rapidly to levels similar to those of untreated cells. To monitor this process, we analyzed acetylated histone H3 in SW13(vim-) cells by Western blot analysis, because untreated SW13(vim-) contain only a low level of this modified form of histone H3 (Figure 4 ). When SW13(vim-) cells were treated with FK228, levels of acetylated H3 were elevated dramatically as expected, and this increase was sustained for 1 day after removal of FK228, possibly due to residual HDAC inhibitor in the treated cells. However, levels of acetylated H3 soon dropped to the original level: this decrease was much more rapid than that of Brm protein.
It was recently reported that Brm protein is a target of histone acetyl transferases, and that treatment with HDAC inhibitors such as trichostatin A causes efficient acetylation of exogenously introduced Brm protein, with a concomitant increase in the exogenous Brm level (Bourachot et al., 2003) . We believe that the prolonged expression of Brm protein after HDAC inhibitor treatment is not explained by induced acetylation of endogenous Brm protein. It is because Figure 4 Time course of Brm protein expression in A427 and SW13(vim-) cells after HDAC inhibitor treatment. These Brmdeficient cell lines were grown for 3 days in the presence of FK228 (1.0 ng/ml for A427 and 0.7 ng/ml for SW13(vim-)). After removing FK228 (day 0), each cell line was grown for additional 1 to 14 days (days 1-14), and whole-cell extracts or total RNA were prepared on the indicated day. For SW13(vim-) cells, acetylated histone H3 and Brm mRNA levels were also quantified. Total cellular extracts (20 mg each) were immunoblotted with anti-Brm or antiacetylated histone H3 antibody. Total RNA (300 ng) was used for RT-PCR of Brm mRNA Biogenesis and antioncogenic potential of Brm N Yamamichi et al SW13(vim-) cells on days 3-14, where HDAC inhibitor retains no activity judged by the level of acetylated histone H3, still synthesize a large amount of Brm protein.
Brm protein expressed in response to HDAC inhibitors is functional and supports retroviral gene expression Transgene expression by an MuLV-based retrovirus vector is rapidly silenced in human tumor cell lines deficient in Brm, and this rapid silencing can be attenuated by exogenous transduction of Brm (Mizutani et al., 2002) . In our previous study, we developed an assay to allow sensitive quantification of retroviral gene silencing that occurs within 4 days after the infection of LacZ virus, where the degree of retroviral gene silencing is defined as the 'mosaic colony ratio'. To examine whether Brm protein induced by HDAC inhibitor is biologically functional, we performed this assay to check the retroviral gene silencing, with the cell lines before and after HDAC inhibitor treatment.
Without the HDAC inhibitor treatment, the mosaic colony ratios of Brm-deficient cell lines were high (66-91%) and those of Brm-expressing cell lines were low, confirming our previous finding that functional Brm, but not BRG1, is essential for maintenance of gene expression by MuLV-based retrovirus (Table 2) . We observed one clear exception: A204 cells, which do not produce functional Ini1 protein but do express Brm protein, have the very high mosaic colony ratio of 75%. We would like to expand our previous model and conclude that the functional Brm-type SWI/SNF complex containing the Ini1 subunit is essential for stable expression of retrovirus.
When the seven Brm-deficient cell lines were treated with HDAC inhibitors for 3 days and cultured 1 day in the absence of the reagent, all expressed Brm protein, as shown in Figure 3 . We performed the mosaic colony assays with these Brm-induced cells, and six cell lines showed significant reduction of mosaic colony ratio, indicating that they acquired the ability to maintain MuLV-based retrovirus expression (Table 2 ). These results indicate that Brm protein produced in response to HDAC inhibitors is biologically functional. The one exception was G401 cells, whose mosaic colony ratio after the treatment was similar to that of untreated cells. This observation can be explained by the fact that functional Brm-type SWI/SNF complex would not be formed in Ini1-deficient G401 cells, even if Brm protein is induced. Together with the finding of the high mosaic colony ratio of A204 cells described above, the idea that the Ini1 subunit is essential for stable retroviral gene expression is further reinforced.
The kinetics of induced Brm protein expression revealed that SW13(vim-) and A427 cells retain very low expression of Brm, even 2 weeks after the removal of FK228 (Figure 4 ). When these cells were transduced with a LacZ virus for the mosaic colony assay, SW13(vim-) and A427 cells still showed significant suppression of retroviral gene silencing with mosaic colony ratios of 48 and 41%, respectively.
Transient treatment with HDAC inhibitors suppresses oncogenic potential of Brm-deficient cell lines
From the viewpoint of oncogenic potential, we next investigated the effect of prolonged epigenetic induction of Brm protein. To evaluate invasive potential, we first performed a tumor invasion assay. Of the seven Brmdeficient cell lines examined, only PA-1 exhibited clear invasion in collagen gel. PA-1 cells were treated with FK228 for 3 days, grown for an additional 24 h in the absence of FK228, and injected into collagen gel. In the embedded culture, untreated PA-1 cells showed clear invasion on days 7-10, whereas FK228-treated PA-1 cells showed drastically reduced invasive activity (Figure 5a ). When FK228-treated PA-1 cells were grown as monolayer cultures for 1 month, the growth rate was no different from that of untreated cells. These results indicate that transient treatment with HDAC inhibitor conferred on this cell line a less oncogenic phenotype.
To examine whether the Brm gene induced by the HDAC inhibitor treatment is responsible for the antioncogenic potential, PA-1 cells that express short hairpin (sh) RNAs targeting against the Brm gene were prepared. For this purpose, we constructed three species of retrovirus vectors (shBrm-1, shBrm-2, and shBrm-4), which target different regions of the Brm gene, respectively. At a multiplicity of infection of three for each vector, these three shBrm viruses were introduced into a PA-1 culture. The transduced PA-1 cells did not express Brm protein at all, even after the FK228 treatment, as judged by Western blotting. These cells were treated with FK228 in the same above-mentioned manner, and the tumor invasion assay was performed in the absence of the inhibitors. As shown in Figure 5a , they exhibited an obvious invasion in collagen gel like untreated PA-1 cells. Therefore, we concluded that Brm protein induced by FK228 is directly involved in reducing the oncogenic potential.
We next screened all of the Brm-deficient cell lines listed in Table 1 for the ability to form colonies in soft agar, and found that only SW13(vim-) and NCC-IT cells formed colonies. When both cells were seeded in soft agar 1 day after FK228 treatment, colony formation was observed to be drastically reduced, whereas no significant reduction was observed when HeLa-S3 cells, which are competent for SWI/SNF complex, were treated with FK228 (Figure 5b ). These results again support our hypothesis that induction of Brm expression by FK228 reduces the oncogenic potential of Brmdeficient cell lines. Next, we checked the ability to form colonies in soft agar with shBrm-expressing SW13(vim-) cells, but these cells showed reduction in anchorageindependent growth. It was probably because FK228 treatment induce not only Brm but also BRG1 in SW13(vim-) cells (Yamamichi-Nishina et al., 2003) , and the shBrm virus transduction did not affect the induction of another anti-oncogene, BRG1. To produce shBRG1 viruses that knock down the BRG1 expression, we designed four kinds of shBRG1 virus, but none of them inhibited BRG1 efficiently, and we could not establish the cells in which expression of BRG1 was reduced to less than 20% of the parental cell. Making use of shBrm viruses, we were able to prove that Brm expression affects the invasive activity of PA-1 cells, but the relationship between the Brm induction and anchorage-independent growth in SW13(vim-) cells could not be demonstrated.
Exogenous expression of the Brm gene in SW13(vim-) cells suppresses anchorage-independent growth
When the Brm gene is introduced into cells that do or do not express endogenous Brm, exogenous expression of Brm protein is strongly attenuated (Bourachot et al., 2003) , although the underlying molecular mechanism is still not fully understood. We previously showed that expression of exogenous Brm with Brm-virus can attenuate the rapid silencing of retroviral gene transcription in SW13(vim-) and C33A cells by autoregulatory mechanisms, but the stable transductants show only marginal Brm expression (Mizutani et al., 2002) . Such Brm-virus-infected cells stably retain Brm function, as judged by expression of endogenous genes under the control of AP-1 (Yamamichi-Nishina et al., 2003) . These cells also retain the ability to recover from retrovirus gene silencing: the mosaic colony ratio of Brm-virus-infected SW13(vim-) cells was 41%. When such Brm-virus-infected SW13(vim-) cells were assayed for anchorage-independent growth, we found that the colony number of infected cells was much lower than that of control virus-infected cells (Figure 5c ). A similar reduction in colony number was observed when BRG1-virus was used. These results indicate that introduction of Brm or BRG1 has an antioncogenic effect on this cell line, which lacks expression of both endogenous BRG1 and Brm. Such reduction in anchorage-independent growth was not observed when HeLa-S3 cells were infected with Brm-or BRG1-virus (Figure 5c ).
Discussion
Brm-deficient human cell lines are derived from various types of tumors (Table 1) , including embryonic carcinomas and non-small-cell lung carcinomas. We noticed that these cell lines share unique cellular properties. Their cloning by end point dilution was usually difficult, and conditioned medium was needed for the efficient cloning (N Yamamichi and H Iba, unpublished observation). They were often insensitive to conventional assay systems to evaluate oncogenic potential such as colony formation in soft agar. All the Brm-deficient cell lines are examined by the three-dimensional collagen gel embedded culture method, but we detected clear invasive activity only in PA-1 cells (Figure 5a ). We could evaluate anchorage-independent growth of SW13(vim-) and NCC-IT cells by colony formation in soft agar (Figure 5b) , however, relatively large number of these cells was needed to be seeded for colony formation. Exogenous introduction of the Brm gene as well as indirect induction of Brm protein expression by HDAC inhibitors drastically reduced these oncogenic Table 2 , grown in the absence of FK228 for an additional 24 h, and seeded in soft agar. The number of colonies formed by untreated cells was taken as 100%. The error bar shows the standard deviation based on the results of three experiments. (c) Effects of exogenous expression of Brm and BRG1 on colony-forming activity in soft agar. SW13(vim-) and HeLa-S3 cells were infected with Brm-virus, BRG1-virus, or control virus, selected with 1.0 mg/ml puromycin, and seeded in soft agar. The numbers of formed colonies by untreated cells were taken as 100%. The error bar shows the standard deviation based on the results of three experiments features, whereas such treatments did not significantly affect the oncogenic potential of human tumor cell lines that have functional SWI/SNF complex. On the basis of these results, we propose that the Brm gene has antioncogenic potential. Difficulties in estimating oncogenic potential of Brm-deficient cell lines in vitro by conventional methods, however, suggest that it remains to be clarified what kinds of oncogenic parameters are most sensitively affected by the loss of Brm expression. In this regard, it is noteworthy that loss of BRG1/Brm in human lung cancer cell lines and primary lung cancers is reported to correlate with poor prognosis (Reisman et al., 2003) .
It is interesting that all Brm-deficient cell lines examined here carry a functional Brm gene, and Brm deficiency is caused by suppression at the post-transcriptional level. In all of these cell lines, the Brm gene was transcribed efficiently, but mature mRNA as well as hnRNA was not detectable. Therefore, the processing of the primary Brm transcript to mature mRNA would be affected. We cannot exclude the possibility that Brm mRNA transport is also attenuated or that Brm mRNA is unstable. For typical tumor suppressor genes, such as p53, Rb, and Ini1, loss of function is usually caused by point mutations in the coding sequence or by deletion of the entire locus (Shimizu et al., 1994; Jia et al., 1997; Biegel et al., 1999) . Several other tumor suppressor genes, such as p16(INK4a) and p15(INK4b), are often silenced at the level of transcription (Esteller, 2002) . Therefore, silencing of the Brm gene at the posttranscriptional level is a very unique property among genes with antioncogenic potential. Although molecular mechanisms remain unclear, the post-transcriptional suppression can be attenuated for at least 2 weeks by transient treatment with HDAC inhibitors. This attenuation period is sufficient to either reduce ability of anchorage-independent growth or invasion into collagen gel, thus indicating that HDAC inhibitors may be effective in cancer therapies for Brm-deficient tumor cells. In addition, the HDAC inhibitor-treated cells were shown to be resistant to retroviral gene silencing during this period, suggesting that HDAC inhibitors may be helpful for the cancer gene therapy with retrovirus vectors.
The human SWI/SNF complex utilizes either Brm or BRG1 catalytic subunit to remodel nucleosomes. We found that functional Brm-type SWI/SNF complex, rather than BRG1-type SWI/SNF complex, is directly involved in stable expression of MuLV-based retrovirus probably as a trithorax-G complex, which has been shown to maintain expression of activated genes (Mizutani et al., 2002) . We also present evidence that Ini1 is an essential subunit for this function; loss of Ini1 yielded the same phenotype of rapid retroviral gene silencing found in Brm-deficient cells. Therefore, we believe that it is unlikely that Brm alone or any other complex containing Brm, but not Ini1, is involved in this function. Consistent with our observation, SNF5, the yeast homologue of Ini1, was reported to be the essential subunit for SWI/SNF complex activity (Geng et al., 2001 ).
When we consider the function of the entire SWI/ SNF complex in tumor formation, many questions still remain to be solved. For example, it is not clear whether each SWI/SNF subunit functions to suppress tumor formation as an integral part of the entire complex. Analyses of knockout mice of each subunit of SWI/SNF complex showed that both Ini1 and BRG1 heterozygotes were predisposed to malignant tumors (Bultman et al., 2000; Klochendler-Yeivin et al., 2000; Barker et al., 2001) , but phenotypes of the tumors are quite different. It was also reported that SWI/SNF complex formation and the expression of many BRG1-dependent genes are independent of Ini1 expression (Doan et al., 2004) . It is therefore possible that each of Brm, BRG1, and Ini1 subunits could be a component of other distinct protein complexes that manifest their own tumorsuppressing potential. It is also possible that several additional mutations in other genes would be needed before the loss of SWI/SNF function establish stable neoplastic properties, as the SWI/SNF complex is involved in so many normal cellular functions including transcription, replication, recombination, and cell cycle regulation.
Materials and methods

Cell lines
Human tumor cell lines SW13(vim-) (Yamamichi-Nishina et al., 2003) , C33A, PA-1, NCC-IT, NCI-H522, A427, H1299, A549, G401, A204, MDA-MB435, SW620, HeLa-S3, and PtG-S2 (prepackaging cell line for retrovirus vector production) were maintained in high glucose DMEM supplemented with 10% fetal calf serum (FCS) (Gibco/Invitrogen Corp., Carlsbad, CA, USA) and incubated at 371C. EB5 (mouse embryonic stem cell) was maintained at 371C in GMEM (Sigma) supplemented with 10% FCS, 1% nonessential amino acids (Gibco/Invitrogen Corp.), and leukemia inhibitory factor at 10 3 units/ml. NIH3T3 (mouse fibroblastlike cell) was maintained at 371C in low glucose DMEM supplemented with 10% calf serum (Gibco/Invitrogen Corp.). When cells were treated with HDAC inhibitors, FK228 (a gift from Fujisawa Corporation, Osaka, Japan) at 0.7-1.6 ng/ml or CHAP31 (a gift from the Japan Energy Corporation, Saitama, Japan) at 5.5 nM were added to the culture medium.
Western blotting
Cells were lysed with 1.5 Â sample buffer (91.8 mM Tris-HCl (pH 6.8), 525 mM b-mercaptoethanol, 14.7% glycerol, 3% SDS), and boiled for 10 min at 961C for denaturation. Wholecell extracts (20 mg each) were separated by electrophoresis on 6% SDS polyacrylamide gels (for Brm and BRG1) or 10% SDS polyacrylamide gels (for Ini1 and acetylated histone H3), transferred to polyvinylidene difluoride (PVDF) membranes, and immunostained with anti-Brm rabbit polyclonal antibody (Transgenic Inc., Kumamoto, Japan), anti-BRG1 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-BAF47/Ini1 mouse monoclonal antibody (BD Transduction Laboratories, Lexington, KY, USA), or antiacetylated histone H3 antibody (Upstate Biotechnology, Lake Placid, NY, USA). Specific bands were detected with an ECL kit (Amersham, Piscataway, NJ, USA).
Genomic PCR
Total cellular DNA was prepared using DNA isolation reagent (Wako Pure Chemical Industries, Osaka, Japan). Genomic DNA was amplified using Ex-Taq (Takara Bio Inc., Shiga, Japan) with an initial denaturation at 951C for 9 min followed by 28 cycles of 951C for 1 min, 601C for 1 min, and 721C for 1 min. The primer pairs were 5 0 -gttatatgtcaccacacccatc-3 0 and 5 0 -cagatggtctgttgtagttaac-3 0 for the fourth exon of Brm, and 5 0 -gtgaacagtcagaaggaagt-3 0 and 5 0 -ttctcatctgaacaggtgat-3 0 for the 34th exon (including 3 0 -noncoding sequence) of Brm. 0 -tatctctctttcagggttgtc-3 0 (locating in third intron) and 5 0 -cagatggtctgttgtagttaac-3 0 (locating in fourth exon) for the 5 0 -region of Brm, and 5 0 -gaattatgatctcaccc cagcctt-3 0 (locating in 32nd intron) and 5 0 -actcactgggtagaaat gagacaggggagg-3 0 (locating in 33rd exon) for the 3 0 -region of Brm. RNA was reverse transcribed for 30 min at 501C, and for Brm and BRG1 mRNA, cDNA was amplified with an initial denaturation at 941C for 3 min followed by 30 cycles of 941C for 30 s, 661C for 2 min, and 721C for 1 min. For Ini1 mRNA, cDNA was amplified with an initial denaturation at 941C for 3 min followed by 30 cycles of 941C for 30 s, 621C for 1 min, and 721C for 1 min. For Brm hnRNA, cDNA was amplified with an initial denaturation at 941C for 3 min followed by 35 or 40 cycles of 941C for 30 s, 581C for 1 min, and 721C for 1 min.
RT-PCR
Nuclear run-on transcription assay
Nuclei were isolated from 2x10 7 cells of each cell line. Transcript elongation assay was performed as described previously (Yamamichi-Nishina et al., 2003) , and RNA labeled with [a-32 P]UTP was isolated from each sample. All samples had very close total radioactivity and were hybridized to Hybond N þ filters that were slot-blotted with several plasmid DNAs (5 mg)
.1-collagenase, and pCR2.1-b-actin. As a control, pCR2.1 or pBluescriptSK( þ ) was also slot-blotted. Construction of these plasmids was described previously (Yamamichi-Nishina et al., 2003) .
Retrovirus vectors
Vesicular stomatitis virus G protein (VSV-G)-pseudotyped, MuLV-based replication-defective retrovirus vectors were prepared with prepackaging cell line PtG-S2 (Arai et al., 1998) or prepackaging cell line PLAT (Morita et al., 2000) .
Brm-virus, BRG1-virus, and control virus were produced by introducing pBabe-hBrm-IRESpuro, pBabe-hBRG1-IRESpuro, and pBabe-IRESpuro, respectively, into PtG-S2 cells (Mizutani et al., 2002) . MFGnlsLacZ, which encodes LacZ with a nuclear localization signal, was used as the LacZ virus (Ui et al., 2000) . To produce a retroviral vector expressing short hairpin RNA (shRNA) to inhibit Brm expression, oligonucleotides 5 0 -ctagcggatccatgagaattcg-3 0 and 5 0 -tcgacgaattctcatggatccg-3 0 were inserted into the NheI-SalI site of modified pQCXIH vector (Clontech, Palo Alto, CA, USA), so as to generate BamHI and EcoRI restriction sites in the U3 region located in 3 0 -long terminal repeat. Next, CMV promoter-IRES-hygromycin of the pQCXIH-based plasmid was replaced by the fragment carrying SV40 promoterpuromycin from pBabe-puro plasmid (Ui et al., 2000) to generate a retroviral vector designated as pSSSP (pSINsiRNA-SV40puro). pmU6 was constructed as reported previously (Yu et al., 2002) , and to produce the pmU6-shRNA cassette, each of following oligonucleotide pairs were annealed and inserted into the BbsI-EcoRI site of pmU6: shBrm-1 corresponding to nt 2998-3018 of Brm coding region, shBrm-2 corresponding to nt 225-245 of Brm coding region, and shBrm-4 corresponding to nt 5425-5445 of Brm coding and noncoding region. BamHI-EcoRI fragments of each pmU6-shRNA cassette were subcloned into the BamHI-EcoRI site of pSSSP. Three types of shBrm virus were produced by introducing pSSSP-shBrm-1, pSSSP-shBrm-2, and pSSSPshBrm-4 into PLAT cells (Morita et al., 2000) with the plasmid coding VSV-G (Arai et al., 1998) .
Mosaic colony assay
All the cell lines were transduced with LacZ virus at a low multiplicity of infection (about 0.1-0.5) to minimize introduction of multiple proviral copies into a single cell. To complete the retroviral integration, the transduced cells were grown for 24 h and seeded at very low density for isolation of individual colonies. Cells were grown for an additional 72 h to form colonies consisting of 6-20 cells. These colonies were fixed and stained with colorant solution (5 mM K 3 Fe(CN) 6 , 5mM K 4 [Fe(CN) 6 ] Á 3H 2 O, 2 mM MgCl 2 , 1 mg/ml X-gal) to examine LacZ expression. Formed colonies were classified into three types: 'positive', in which all cells express LacZ; 'negative', in which no cells express LacZ; and 'mosaic', which contain both LacZ-positive and LacZ-negative cells. The 'mosaic colony ratio' was calculated as the number of mosaic colonies divided by the sum of the number of positive colonies and the number of mosaic colonies.
Tumor invasion assay (3D collagen gel embedded culture method)
To prepare collagen gels for tumor invasion assay, Cellmatrix Type I-A Collagen Kit (Nitta Gelatin Inc., Osaka, Japan) was used. Type I-A collagen was mixed with 5 Â DMEM and sterile constitution buffer (2.2 g NaHCO 3 in 100 ml 0.05 N NaOH/200 mM HEPES) at a 7 : 2 : 1 ratio on ice. Reconstituted collagen solution (200 ml) was added to a 24-well plate to make the bottom collagen gel layer and maintained at 371C for 30 min until solid. Fresh reconstituted collagen solution (600 ml) was poured onto the solidified bottom layer, and the culture plate was incubated at 371C for an additional 6 min. Cells (5 Â 10 3 ) suspended in 5 ml of culture medium were then injected into the center of this top layer. The culture plate was incubated at 371C for 25 min to complete solidification. Finally, 400 ml of culture medium was poured onto these gel layers, and the cells embedded in the top layer were grown for 7-12 days at 371C.
Colony formation in soft agar
SW13(vim-), NCC-IT, and HeLa-S3 cells were seeded into 60-mm dishes as a suspension of 0.4%. Noble agar (BD Company, Sparks, MD, USA) in high glucose DMEM supplemented with 10% FCS and 0.5 mg/ml amphotericin B (Sigma). The upper agar layers were on top of beds of 0.5% Bacto agar (BD Company) in high glucose DMEM supplemented with 10% FCS and 5.0 mg/ml amphotericin B (bottom agar layers). Cultures were incubated at 371C for 28 days, and the resulting colonies were counted. The average of three experiments is shown with standard deviation.
